Previous reports showed that high RNA levels of CD47 was associated with worse PFS and OS in NSCLC patients.23 Furthermore, overexpression of CD47 was associated with tumor characteristics (from the TNM Classification of Malignant Tumors), clinical staging, lymph node metastasis and distant metastasis in NSCLC patients.22, 24 Although high CD47 expression could be a potential prognosis biomarker, more studies are necessary to determine the best cutoff for this molecule. The gene discussed is CD47; the disease is cancer.